Co-Authors
This is a "connection" page, showing publications co-authored by Frederick Hayden and Abdulaziz Al-Dawood.
Connection Strength
0.389
-
Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome. N Engl J Med. 2020 10 22; 383(17):1645-1656.
Score: 0.057
-
Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. Clin Infect Dis. 2020 04 15; 70(9):1837-1844.
Score: 0.055
-
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-ß1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020 Jan 03; 21(1):8.
Score: 0.054
-
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018 03 15; 197(6):757-767.
Score: 0.047
-
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-ß1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018 Jan 30; 19(1):81.
Score: 0.047
-
Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study. Crit Care Med. 2017 10; 45(10):1683-1695.
Score: 0.046
-
Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerg Infect Dis. 2016 09; 22(9):1554-61.
Score: 0.043
-
Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015; 4:709.
Score: 0.040